Unknown

Dataset Information

0

Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.


ABSTRACT: The abnormal trafficking of CD34+ cells is a unique characteristic of primary myelofibrosis (PMF). We have further studied the behavior of PMF CD34+ cells by examining their homing to the marrow and the spleens of nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. Following the infusion of PMF and normal granulocyte colony-stimulating factor-mobilized peripheral blood (mPB) CD34+ cells into NOD/SCID mice, reduced numbers of PMF CD34+ cells and granulocyte-macrophage colony-forming unit (CFU-GM) compared with mPB were detected in the marrow of these mice, whereas similar numbers of PMF and mPB CD34+ cells and CFU-GM homed to their spleens. The abnormal homing of PMF CD34+ cells was associated with reduced expression of CXCR4, but was not related to the presence of JAK2V617F. The sequential treatment of PMF CD34+ cells with the chromatin-modifying agents 5-aza-2'-deoxycytidine (5azaD) and trichostatin A (TSA), but not treatment with small molecule inhibitors of JAK2, resulted in the generation of increased numbers of CD34+CXCR4+ cells, which was accompanied by enhanced homing of PMF CD34+ cells to the marrow but not the spleens of NOD/SCID mice. Following 5azaD/TSA treatment, JAK2V617F-negative PMF hematopoietic progenitor cells preferentially homed to the marrow but not the spleens of recipient mice. Our data suggest that PMF CD34+ cells are characterized by a reduced ability to home to the marrow but not the spleens of NOD/SCID mice and that this homing defect can be corrected by sequential treatment with chromatin-modifying agents.

SUBMITTER: Wang X 

PROVIDER: S-EPMC3234420 | BioStudies | 2009-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6768666 | BioStudies
2002-01-01 | S-EPMC150411 | BioStudies
1000-01-01 | S-EPMC3031385 | BioStudies
2012-01-01 | S-EPMC3250442 | BioStudies
1000-01-01 | S-EPMC3484080 | BioStudies
2007-01-01 | S-EPMC1847625 | BioStudies
1000-01-01 | S-EPMC1895911 | BioStudies
1000-01-01 | S-EPMC539190 | BioStudies
1000-01-01 | S-EPMC4485368 | BioStudies
1000-01-01 | S-EPMC4827391 | BioStudies